RxDoctor Payments Data

Yolanda Mejia

Family · Frederick, MDNPI 1477254233

Payments from drug & device makers

$3,216in general payments, 2019–2025

Across 58 payments — averaging $55.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Nevro Corp.$579
  • Collegium Pharmaceutical, Inc.$174
  • AbbVie$142
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$66
  • Averitas Pharma Inc.$43
  • plus $137 from 6 others

What the payments were for

  • Travel & lodging$1,14336%
  • Food & beverage$2,07264%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,216 in reported general payments places this provider in the 85th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$110,283
Medicare patients
233
Services billed
1,081

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate19$29,563
BelbucaBuprenorphine Hcl15$13,301
MovantikNaloxegol Oxalate24$9,504
Xtampza ErOxycodone Myristate18$8,667
Lidocaine95$7,942
Oxycodone Hcl449$7,460
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen228$5,112
OxycontinOxycodone Hcl21$4,793
Gabapentin358$4,030
Pregabalin213$3,163
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen119$2,971
Diclofenac Sodium121$2,701
Tizanidine Hcl235$2,229
Morphine Sulfate ErMorphine Sulfate58$1,778
Cyclobenzaprine Hcl84$1,264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$28$29,56319 claims
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$174$21,96833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,843 family providers in Maryland.

Other family in Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →